Op2Lysis SAS
117, avenue Victor Hugo
92100 Boulogne-Billancourt
France

www.op2lysis.com

PRESS RELEASE
October, 10th 2024
Normandy Region & European funding for the ThromboSTROKE collaborative project

Op2Lysis Secures Public Funding for the THROMBO-STROKE Collaborative Research Project Focused on Developing New Models for Ischemic Strokes

Boulogne-Billancourt, October 8, 2024 – Op2Lysis, a biotechnology company developing the first drug to evacuate hematomas formed as a result of cerebral hemorrhage, is pleased to announce the receipt of public funding for its collaborative research project, THROMBO-STROKE. This project, which will run from October 2024 to September 2027, focuses on developing new translational models for ischemic stroke and will be carried out in partnership with Inserm U1237, led by Professor Denis Vivien. The funding is provided by the Normandy Region and the FEDER FSE+ FTJ Normandie program.

The THROMBO-STROKE project aims to address a major gap in ischemic stroke research. Although experimental models have been significantly refined in recent years, they lack translationality in light of the latest data obtained from patients. It is now well established that these experimental models do not adequately reflect the heterogeneity of clots observed in clinical settings, which is critical to predict the effectiveness of ischemic stroke treatment (thrombolysis). The project's goal is to develop new models that take this heterogeneity into account, in order to both improve the understanding of the pathology and enhance the predictive power of preclinical models, thereby stimulating industrial development.

Op2Lysis has already demonstrated its expertise in creating complex models, notably by developing a preclinical human hematoma model for cerebral hemorrhage, enabling the simulation of clinical intervention and prediction of thrombolytic efficacy. This pioneering work was published internationally in 2023 in the prestigious *Brain* journal, enhancing the company's visibility and reinforcing its leadership position in hemorrhagic stroke research. The company's objective is to capitalize on its experience and expand its expertise across all types of strokes.

Inserm U1237, led by Professor Denis Vivien, recipient of the Danièle Hermann Award in 2023 and renowned for its cutting-edge research on ischemic stroke mechanisms, brings scientific and technical expertise to the project. Translationality is a key goal of the research team, with access to samples from the InnovaBIO Biological Resource Center (CRB) at the Caen University Hospital, which will help advance the project.

Dr. Jérôme PARCQ, Chief Scientific Officer (CSO) of Op2Lysis, stated:

> *"This public funding highlights Op2Lysis' expertise in the development of predictive models of blood clots and represents significant local support for Op2Lysis. It strengthens our collaborations at the Cyceron site in Caen, and scientifically, it enables us to further consolidate our well-established expertise in developing translational models. With THROMBO-STROKE, we aim to push the boundaries of preclinical models by improving ischemic stroke models and enhancing their predictive power to stimulate industrial innovation. We are eager to contribute to solutions, which, though early in the value chain, will ultimately improve patients' quality of life."*

Op2Lysis remains committed to advancing stroke treatment through innovative research and collaboration, confident that the THROMBO-STROKE project will lead to significant progress in both scientific knowledge and clinical applications.

For further information, please contact:

Christophe Gaudin, CEO
christophe.gaudin@op2lysis.com
+33 607 979 008
www.op2lysis.com

Jérôme Parcq, CSO
jerome.parcq@op2lysis.com
+33 615 270 969
https://www.linkedin.com/company/op2lysis

About Op2Lysis - www.op2lysis.com

Op2Lysis is a biotechnology company specialising in the development of novel therapies to address unmet needs in cerebrovascular diseases. With its first drug, O2L-001, Op2Lysis is dedicated to developing the first medical treatment for deep hemorrhagic stroke, the most debilitating form of stroke. Op2Lysis aims to become a leader in the development of treatments for all forms of cerebral hemorrhage. Op2Lysis benefits from the dynamic ecosystems of the regions in which the company is based, Caen and Liège.

Op2Lysis SAS: 117 avenue Victor Hugo, 92100 Boulogne-Billancourt, France
GIP Cyceron, Boulevard Henri Becquerel, 14000 Caen, France
Op2Lysis Development SA : Légia Park, Boulevard Patience et Beaujonc, 3, 4000 Liège, Belgium

About O2L-001
O2L-001 is a locally administered treatment designed to liquefy the intracerebral hematoma that has formed following a cerebral hemorrhage, in order to evacuate it and reduce its deleterious mass effect. O2L-001 has been specifically designed for large, deep hematoma. Its development is based on documented clinical proof of concept (MISTIE program), including the demonstration of a robust association between reduction in blood volume and reduction in disability. The competitive advantages of O2L-001 observed in the best translational models indicate the potential for major efficacy and increased safety in this therapeutic indication. O2L-001 should radically change practice in this therapeutic indication.O2L-001 scientific results are published in high impact factor peer-revewied journals: Journal of Cerebral Blood Flow and Metabolism (Q1 in Neurosciences and Hematology - 2018 - https://doi.org/10.1177/0271678x17719180) and Brain (IF=14.8, ranked 5 out of 212 in clinical neurology – 2023 - https://doi.org/10.1093/brain/awad237).

About NANOp2Lysis
NANOp2Lysis® is Op2Lysis' proprietary platform, combining four key elements for the development of breakthrough therapeutic solutions: a unique vectorization technology; industrial know-how to produce clinical-quality batches; preclinical expertise including predictive and translational models, a first in this field; and regulatory expertise to accelerate market access.